Antifibrinolytics: tranexamic acid in bleeding, clot and seizure risks, and kidney factors

How an antifibrinolytic changes bleeding

After injury the body forms a fibrin clot and, at the same time, starts dissolving clots through plasmin. Tranexamic acid blocks the activation of plasminogen to plasmin, so clots already formed are broken down more slowly. It does not create new clotting factors, raise platelet counts or reverse anticoagulants, which is a common exam misunderstanding.

Because it protects existing clot, tranexamic acid is one tool within a bleeding plan, not the plan itself. Source control, blood products, uterotonics after birth and surgery remain central. Uses range from heavy menstrual bleeding and nosebleeds treated with tablets, to dental extraction in haemophilia, to intravenous use in major haemorrhage.

Early use in trauma and postpartum haemorrhage

In trauma, reference guidance places early tranexamic acid, within about three hours of injury, inside massive transfusion protocols. Timing matters because benefit is linked to early administration, so the nurse records the time of injury and the time of the dose. A question that delays it while waiting for laboratory results usually misses the point.

In postpartum haemorrhage, trial evidence supports giving tranexamic acid early, ideally within three hours of birth, alongside uterotonics such as oxytocin rather than as a last resort. It does not replace fundal massage, uterotonics or assessment for retained tissue or trauma. The nurse continues measuring blood loss, vital signs and uterine tone while the drug is given.

Clot risk and who should not receive it

Because it shifts the balance toward clot persistence, tranexamic acid is contraindicated in active intravascular clotting, and patient guidance warns against it for people with previous deep vein thrombosis or pulmonary embolism. The label also advises avoiding combination with factor IX complex or anti-inhibitor coagulant concentrates, and with hormonal contraceptives because of additive thrombotic risk.

After a dose, the nurse watches for a painful, swollen, warm limb, sudden breathlessness, chest pain or coughing blood, and new neurological deficits. Each warrants urgent escalation. The label contraindicates use in subarachnoid haemorrhage because of cerebral oedema and infarction risk, so recent brain bleeding history is checked before giving the drug outside a protocol.

Seizures, route errors and kidney function

Seizures are linked to high doses and to accidental neuraxial administration. The label describes serious and fatal reactions, including seizures and arrhythmias, when tranexamic acid was injected into the spinal or epidural space by mistake. The nurse therefore checks the product label at the bedside and confirms the intravenous route before every dose.

Tranexamic acid is cleared by the kidneys, and the label reduces dosing as serum creatinine rises. Nurses report kidney impairment, review the latest creatinine and urine output, and flag any order that does not reflect the patient's renal status. Visual disturbances are listed among rare serious effects, so changes in eyesight are reported. Other listed effects include nausea, vomiting, diarrhoea, dizziness and hypotension. For long courses, the label recommends eye examinations because retinal changes were seen in animal studies.

A hypothetical trauma bay scenario

Imagine an adult brought in an hour after a road collision with hypotension, tachycardia and suspected internal bleeding. The massive transfusion protocol is activated and tranexamic acid is ordered. The options are to wait for a coagulation panel, give it only once surgery is booked, give it now as ordered and document the time, or substitute vitamin K.

Giving it now as ordered is the best action because benefit depends on early administration within the protocol window. Waiting for laboratory results or theatre delays a time-sensitive drug, and vitamin K treats a different problem, warfarin-related factor deficiency. The nurse then continues haemodynamic monitoring and watches for thrombosis. This is an invented study example.

Sources and further reading

DailyMed: Cyklokapron (tranexamic acid) injection prescribing information. Contraindications, neuraxial route errors, seizures, thromboembolic interactions, visual disturbances, renal dose adjustment and adverse reactions.

NHS: Who can and cannot take tranexamic acid. Avoidance with previous clots, epilepsy, kidney problems and coagulopathy.

MSD Manual Professional: Approach to the trauma patient. Early tranexamic acid within three hours as part of massive transfusion protocols.

Europe PMC: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN) (Lancet, 2017). Reduced death from bleeding with tranexamic acid in postpartum haemorrhage, especially when given within three hours of birth.